comparemela.com

Latest Breaking News On - Pharvarisnv - Page 2 : comparemela.com

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for

ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor.

United statesUnited kingdomKrung thep mahanakhonMaryann ciminoMarca riedlExchange commissionUniversity of california san diegoEuropean unionAngioedema centerClinical serviceUs hereditary angioedema associationRegional conferenceTreating hereditary angioedema attacksClinical directorAngioedema associationCalifornia san diego

Pharvaris Reports Third Quarter 2022 Financial Results and

Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated in a Type A meeting.

United kingdomBerndt modigDevelopment rd expensesInternational financial reporting standardsAmerican college of allergyDrug administrationInternational accounting standards boardChief executive officerBradykinin symposiumGlobal leadership workshopAmerican collegeAnnual scientific meetingAnnick deschoolmeesterChief human resources officerHuman resourcesForeign private issuer

Pharvaris Announces the Promotion of Annick Deschoolmeester

ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor.

United statesBerndt modigVertalers tolkenMaryann ciminoShire pharmaceuticalsTakeda pharmaceuticalsExchange commissionEuropean unionAnnick deschoolmeesterChief human resourcesChief executive officerExecutive committeeHuman resourcesGlobal headPlasma derived therapiesProvincial hogeschool

Pharvaris to Participate in H C Wainwright 1st Annual

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor.

Maryann ciminoAnnual hereditary angioedemaNasdaq phvs

Pharvaris Participates in the Kinin 2022 Conference

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite.

United statesBerndt modigMaryann ciminoAnne lesageExchange commissionEuropean unionStatement regarding forward lookingAnnual reportNasdaq phvs

vimarsana © 2020. All Rights Reserved.